Rani Isha, Kalsi Avjit, Kaur Gagandeep, Sharma Pankaj, Gupta Sumeet, Gautam Rupesh K, Chopra Hitesh, Bibi Shabana, Ahmad Syed Umair, Singh Inderbir, Dhawan Manish, Emran Talha Bin
MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Haryana, India.
MM School of Pharmacy, MM University, Sadopur, Ambala, Haryana, India.
Ann Med Surg (Lond). 2022 Aug;80:104125. doi: 10.1016/j.amsu.2022.104125. Epub 2022 Jul 12.
In early December 2019, a large pneumonia epidemic occurred in Wuhan, China. The World Health Organization is concerned about the outbreak of another coronavirus with the powerful, rapid, and contagious transmission. Anyone with minor symptoms like fever and cough or travel history to contaminated places might be suspected of having COVID-19. COVID-19 therapy focuses on treating the disease's symptoms. So far, no such therapeutic molecule has been shown effective in treating this condition. So the treatment is mostly supportive and plasma. Globally, numerous studies and researchers have recently started fighting this virus. Vaccines and chemical compounds are also being investigated against infection. COVID-19 was successfully diagnosed using RNA detection and very sensitive RT-PCR (reverse transcription-polymerase chain reaction). The evolution of particular vaccinations is required to reduce illness severity and spread. Numerous computational analyses and molecular docking have predicted various target compounds that might stop this condition. This paper examines the main characteristics of coronavirus and the computational analyses necessary to avoid infection.
2019年12月初，中国武汉发生了一场大规模肺炎疫情。世界卫生组织对另一种具有强大、快速和传染性传播能力的冠状病毒的爆发表示关注。任何出现发热、咳嗽等轻微症状或有去过受污染地区旅行史的人都可能被怀疑感染了新冠病毒。新冠病毒治疗主要集中在治疗疾病症状上。到目前为止，尚未有治疗分子被证明对治疗这种疾病有效。因此，治疗主要是支持性治疗和使用血浆。在全球范围内，众多研究和研究人员最近已开始对抗这种病毒。针对感染的疫苗和化合物也正在进行研究。通过RNA检测和非常灵敏的逆转录-聚合酶链反应（RT-PCR）成功诊断出了新冠病毒。需要研发特定的疫苗来降低疾病的严重程度和传播范围。众多的计算分析和分子对接已经预测出了各种可能阻止这种疾病的靶标化合物。本文研究了冠状病毒的主要特征以及避免感染所需的计算分析。
